<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>&#x682A;&#x5F0F;&#x4F1A;&#x793E;&#x30DE;&#x30A4;&#x30AF;&#x30ED;&#x30F3;</provider_name><provider_url>https://microncro.com</provider_url><author_name>tetsuda@micron-kobe.com</author_name><author_url>https://microncro.com/archives/post/author/tetsudamicron-kobe-com/</author_url><title>The Frontline of Theranostics &#x2014; A KOL&#x2019;s Perspective on Challenges and Future Prospects in Japan | Micron, Inc. | Molecular Imaging CRO Network</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="t1kEdvTG49"&gt;&lt;a href="https://microncro.com/en/archives/post/news20260910/"&gt;The Frontline of Theranostics &#x2014; A KOL&#x2019;s Perspective on Challenges and Future Prospects in Japan&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://microncro.com/en/archives/post/news20260910/embed/#?secret=t1kEdvTG49" width="600" height="338" title="&#x201C;The Frontline of Theranostics &#x2014; A KOL&#x2019;s Perspective on Challenges and Future Prospects in Japan&#x201D; &#x2014; &#x682A;&#x5F0F;&#x4F1A;&#x793E;&#x30DE;&#x30A4;&#x30AF;&#x30ED;&#x30F3;" data-secret="t1kEdvTG49" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://microncro.com/wp-includes/js/wp-embed.min.js
&lt;/script&gt;
</html><description>Nuclear medicine uses radioactive tracers to visualize organ and tissue function, supporting disease diagnosis and treatment. Theranostics, an approach that combines targeted diagnostic imaging and therapy, is opening new possibilities for personalized medicine. In this edition of Micron&#x2019;s ViewPoint, we speak with Professor Seigo Kinuya of Kanazawa University, whose career spans clinical practice, research, education, [&hellip;]</description><thumbnail_url>https://microncro.com/wp-content/uploads/2026/05/OGP_W1200_H630.png</thumbnail_url><thumbnail_width>1200</thumbnail_width><thumbnail_height>630</thumbnail_height></oembed>
